An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

NCT07693608 on ClinicalTrials.gov · last registry update 2026-08-21

A small phase 2 — 45 participants, against a typical 110. Due to report 1 February 2030, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Effect of tirzepatide on self-reported use of stimulants. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: ENROLLING_BY_INVITATION
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: University of Texas Southwestern Medical Center
Sponsor type: Other
Enrollment: 45
Started: 2026-08-19
Primary completion: 2030-02-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Effect of tirzepatide on self-reported use of stimulants

Conditions studied

Obesity · Methamphetamine Use Disorder · Cocaine Use Disorder · Stimulant Use Disorders

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.